SeaStar Medical Pushes Pediatric AKI Treatment with Educational Initiatives
Event summary
- SeaStar Medical is sponsoring the KidneyBee Summit 2026 from July 14 to 16, 2026, at Children’s Hospital Colorado.
- The company will host a webinar on August 11, 2026, focusing on its QUELIMMUNE therapy for pediatric sepsis-associated AKI.
- QUELIMMUNE showed a 77% survival rate in clinical trials versus standard of care, reducing mortality by approximately 50%.
- Real-world data from the QUELIMMUNE SAVE Registry shows a 76% survival rate at Day 60 and 71% at Day 90.
The big picture
SeaStar Medical is positioning itself as a leader in pediatric critical care by advancing awareness and adoption of its QUELIMMUNE therapy. The company’s focus on educational initiatives underscores the significant gaps in clinical protocols for pediatric AKI, a condition with high mortality rates. With the NEUTRALIZE-AKI pivotal trial ongoing for adult patients, SeaStar Medical is poised to expand its impact across multiple acute and chronic kidney diseases.
What we're watching
- Clinical Adoption
- How quickly top-ranked children’s hospitals will adopt QUELIMMUNE therapy following educational initiatives.
- Regulatory Expansion
- Whether SeaStar Medical can secure additional FDA approvals for broader applications of SCD therapy.
- Market Penetration
- The pace at which SeaStar Medical can expand its market share in the pediatric AKI treatment space.
Related topics